<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02222961</url>
  </required_header>
  <id_info>
    <org_study_id>600.2</org_study_id>
    <nct_id>NCT02222961</nct_id>
  </id_info>
  <brief_title>Single Increasing Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Male Volunteers</brief_title>
  <official_title>A Single-blind, Placebo-controlled Single Increasing Dose Tolerance Study in Healthy Male Volunteers After Intravenous Administration of BIIR 561 CL as Loading Dose (Dosage: 37.5 mg/h - 150 mg/h, Infusion Time 1 Hour) Followed by Maintenance Dose (Dosage: 20 mg/h - 40 to 125 mg/h), Infusion Time 5 Hours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the present study is to obtain information about the safety, tolerability
      and pharmacokinetics of BIIR 561 after continuous intravenous administration of increasing
      doses in healthy young volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 1999</start_date>
  <primary_completion_date type="Actual">June 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 8 days after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant findings in vital functions</measure>
    <time_frame>up to 8 days after drug administration</time_frame>
    <description>blood pressure, pulse rate, respiratory rate, oral body temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant findings in ECG</measure>
    <time_frame>up to 8 days after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant findings in laboratory tests</measure>
    <time_frame>up to 8 days after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration in plasma (Cmax)</measure>
    <time_frame>up to 32 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration in plasma (tmax)</measure>
    <time_frame>up to 32 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>up to 32 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from zero to the last time points with a quantifiable plasma concentration (AUC0-tf)</measure>
    <time_frame>up to 32 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve extrapolated to infinity (AUC0-inf)</measure>
    <time_frame>up to 32 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Mean residence time (MRTtot)</measure>
    <time_frame>up to 32 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma clearance (CLtot)</measure>
    <time_frame>up to 32 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vz)</measure>
    <time_frame>up to 32 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss)</measure>
    <time_frame>up to 32 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount excreted into urine (Ae)</measure>
    <time_frame>up to 32 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time of disposition (MRTdisp)</measure>
    <time_frame>up to 32 hours after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (CLR)</measure>
    <time_frame>up to 32 hours after first drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment>60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BIIR 561 CL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIR 561 CL</intervention_name>
    <arm_group_label>BIIR 561 CL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers

          -  Age 21 to 50 years

          -  Broca index from -20% to +20%

          -  Written informed consent prior to admission to the study

        Exclusion Criteria:

          -  Medical examination, laboratory tests or ECG judged by the investigator to differ
             significantly from normal clinical values

          -  Known gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Known diseases of the central nervous system (CNS) (such as epilepsy), CNS trauma in
             their medical history or with psychiatric or neurological disorders

          -  Known history of orthostatic hypotension, fainting spells or blackouts

          -  Chronic or relevant acute infections

          -  Allergy/hypersensitivity (including drug allergy) which is deemed relevant to the
             trial as judged by the investigator

          -  Intake of a drug with a long half-life (&gt; 24 hours) within at least one month or less
             than ten half-lives of the respective drug before enrolment in the study

          -  Intake of any other drug which might influence the results of the trial during the
             week previous to the start of the study

          -  Participation in another study with an investigational drug within the last two months
             preceding this study

          -  Smoker (&gt; 10 cigarettes or 3 cigars or 3 pipes/day)

          -  Alcohol use of more than 60 g per day

          -  Drug dependency

          -  Excessive physical activities (e.g. competitive sports) within the last week before
             the study

          -  Blood donation within the last 4 weeks (&gt;= 100 ml)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2014</study_first_submitted>
  <study_first_submitted_qc>August 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2014</study_first_posted>
  <last_update_submitted>August 21, 2014</last_update_submitted>
  <last_update_submitted_qc>August 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

